Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

924P - SNS-301 added to pembrolizumab in patients (Pts) with ASPH+ advanced squamous cell carcinoma of the head & neck (SCCHN)

Date

17 Sep 2020

Session

E-Poster Display

Topics

Immunotherapy

Tumour Site

Head and Neck Cancers

Presenters

Alain Algazi

Citation

Annals of Oncology (2020) 31 (suppl_4): S599-S628. 10.1016/annonc/annonc277

Authors

A.P. Algazi1, M. Guarino2, T.J. Panella3, J. Celebi4, I. Csiki4, A. Drumheller4, J. Campbell4, R. Pierce4, W.B. Smith5

Author affiliations

  • 1 Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, 94143 - San Francisco/US
  • 2 Helen F. Graham Cancer Center, Christiana Hospital, Newark/US
  • 3 University Cancer Specialists, University of Tennessee, Knoxville/US
  • 4 Clinical Development, Sensei Biotherapeutics, Inc., 20879 - Gaithersburg/US
  • 5 Noccr/vrg, An AMR Company, LLC, Knoxville/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 924P

Background

Efficacy of anti-PD-1/PD-L1 therapy is attributed to the presence of infiltrating antigen-specific CD8+ T-cells. Despite the success of anti-PD-1/PD-L1 therapy, many pts present with immune desert or immune excluded tumors & only 13-16% of pts respond. Given this low response rate, it is imperative to combine agents which generate or expand anti-tumor T cells such as vaccines with anti-PD-1/PD-L1 therapies. This trial was launched with the objectives of evaluating safety/efficacy in pts that did not respond to anti-PD-1/PD-L1 therapy. SNS-301 is a first-in-class, bacteriophage-based immune activating agent targeting human aspartate β-hydroxylase (ASPH), a tumor associated antigen (TAA) overexpressed in 20+ tumor types. SNS-301 is a self-adjuvanted cancer vaccine consisting of λ-bacteriophage engineered to express an immunogenic fragment of ASPH fused to the phage gpD coat protein, shown to generate immune responses in a phase I study (NCT03120832).

Methods

Full eligibility criteria are described in NCT04034225. Pts are required to have ASPH+ SCCHN, actively receiving pembrolizumab or nivolumab for ≥12 weeks, & have a best response of stable disease (SD) or first evidence of progressive disease (PD). Pts provide a pre-SNS-301 tumor sample an on-treatment tumor biopsy, & an optional biopsy at PD to characterize the tumor microenvironment & correlate with clinical outcomes. SNS-301 with pembrolizumab is given until confirmed PD or unacceptable toxicity. Safety, tolerability, & anti-tumor activity such as objective response rate, duration of response, progression-free & overall survival, immune responses, tumor/immune biomarkers & associated treatment outcome.

Results

As of 18May20 6 pts have started treatment. All 18 screened pts were positive for ASPH. Adverse events were all Grade 1. Of 3 pts eligible for efficacy analysis, 2 pts have SD of 18+ weeks duration & 1 pt had PD. All pts had SD at enrollment (18-68 weeks). Correlative immunological analyses are ongoing & will be presented.

Conclusions

Early clinical data show that the combination of SNS-301 & pembrolizumab has manageable toxicity & capacity to achieve long-term disease stability with potential for responses after further treatment.

Clinical trial identification

NCT04034225; July 16, 2019.

Editorial acknowledgement

Legal entity responsible for the study

Sensei Biotherapeutics, Inc.

Funding

Sensei Biotherapeutics, Inc.

Disclosure

A.P. Algazi: Honoraria (self), Advisory/Consultancy, Research grant/Funding (self), Shareholder/Stockholder/Stock options: OncoSec; Advisory/Consultancy, Shareholder/Stockholder/Stock options: Valitor Biosceinces; Honoraria (self), Advisory/Consultancy: Regeneron; Honoraria (self), Advisory/Consultancy: Array; Research grant/Funding (institution): Acerta; Research grant/Funding (institution): Amgen; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): BMS; Research grant/Funding (institution): Dynavax; Research grant/Funding (institution): Genetech; Research grant/Funding (institution): Idera; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): ISA; Research grant/Funding (institution): LOXO; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Novartis; Research grant/Funding (institution): Sensei Biotherapeutics; Research grant/Funding (institution): Tessa. T.J. Panella: Research grant/Funding (institution): Array; Research grant/Funding (institution): Merck; Research grant/Funding (institution): Amgen; Non-remunerated activity/ies: ASCO. J. Celebi: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment, Officer/Board of Directors: Sensei Biotherapeutics; Shareholder/Stockholder/Stock options: X4 Pharmaceuticals. I. Csiki: Leadership role, Shareholder/Stockholder/Stock options: Sensei Biotherapeutics. A. Drumheller: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment: Sensei Biotherapeutics; Shareholder/Stockholder/Stock options: Inovivo; Shareholder/Stockholder/Stock options: Allogene; Shareholder/Stockholder/Stock options: Merrimack. J. Campbell: Leadership role, Shareholder/Stockholder/Stock options, Full/Part-time employment: Sensei Biotherapeutics. R. Pierce: Leadership role, Research grant/Funding (self), Research grant/Funding (institution), Shareholder/Stockholder/Stock options, Full/Part-time employment: Sensei Biotherapeutics; Research grant/Funding (institution): Juno; Research grant/Funding (institution): Exicure; Research grant/Funding (institution): Minerva Therapeutics; Research grant/Funding (institution): Incyte; Research grant/Funding (institution): X4 Pharmaceuticals; Research grant/Funding (self), Research grant/Funding (institution): AstraZeneca; Research grant/Funding (self), Research grant/Funding (institution): Pulse Biosciences; Research grant/Funding (self), Research grant/Funding (institution), Shareholder/Stockholder/Stock options: Immunomic Therapeutics; Shareholder/Stockholder/Stock options: OncoSec Medical. W.B. Smith: Full/Part-time employment: NOCCR/VRG, An AMR Company, LLC. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.